UroGen Pharma Ltd. (URGN) Discusses Real-World Experiences and Outcomes With ZUSDURI for Recurrent Bladder Cancer Transcript
UroGen Pharma Ltd. recently discussed the real-world experiences and outcomes associated with their treatment ZUSDURI for recurrent bladder cancer. The discussion took place during a conference call at the AUA in Washington, D.C. Key company executives participated in the call to share insights and data on the treatment's effectiveness.
- ▪UroGen Pharma Ltd. is focused on developing treatments for bladder cancer.
- ▪The company highlighted real-world outcomes of their drug ZUSDURI during a recent conference call.
- ▪Executives from UroGen Pharma participated in the discussion to provide insights on treatment effectiveness.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4905817-urogen-pharma-ltd-urgn-discusses-real-world-experiences-and-outcomes-with-zusduri-for"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
